Nimodipine in poor-grade aneurysm patients


Phase N/A Results


Nimodipine treatment was associated with a significantly better outcome (p < 0.001): 21 (29.2%) of 72 nimodipine-treated patients had a good outcome at 3 months after SAH compared to 8 (9.8%) of 82 placebo-treated patients. Delayed ischemic deficits from vasospasm alone were significantly less frequent in the nimodipine group (p < 0.05) with permanent deficits occurring in five nimodipine-treated patients (6.9%) and in 22 placebo-treated patients (26.8%). There was no significant difference in mortality rate or incidence of severe diffuse or moderate diffuse vasospasm between the two groups. There was no significant difference in the incidence or size of infarction on 8-day CT scan, although there was a trend to fewer and smaller infarcts in the nimodipine group.